Abstract: GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Abstract: GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Abstract: GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Abstract: A mobile device that includes an ownership token application program receives user input indicative of a first authentication factor associated with an ownership token bound to an Internet of Things (IoT) device. Responsive to detecting the IoT device in close proximity, the mobile device may obtain a second authentication factor and an IoT device identifier from the IoT device. The mobile device may then provide the obtained factors as authenticating credentials to a token server via a trust application program interface (API). After the server authenticates the mobile device, the server may send the token to the mobile device thereby transferring ownership rights, including access rights, to recipient. The application program and/or the trust API may be configured for one-time access wherein, after the token has been transferred to the mobile device. The discrete electronic device may comprise an Internet of Things (IoT device) that supports wireless, near field communication.

Abstract: GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Abstract: GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Abstract: Aspects of the present invention provide the ability to enforce access methods on data based upon a policy or policies identified within the metadata of a file. The data is self-protected by including or being wrapped with one or more policy/rule identifiers that act as a form of body armor to the data when in transit or in different situations. In embodiments, access is only granted upon successful authentication and compliance with the identified policy or policies. In embodiments, depending upon the conditions and policies, varying level access may be granted. In embodiments, depending upon the conditions and policies, the system may take one or more mitigations or remedial access levels, such as containerizing, sandboxing, granting limited access, or erasing the data.

Abstract: Systems and methods for securing network devices through the use of an out-of-band beacon are described. In some embodiments, a method may include broadcasting, by a gateway, a wireless beacon that is out-of-band with respect to communications between the gateway and a plurality of devices over a network, where the wireless beacon includes a token; receiving an encrypted packet at the gateway as part of the communications; decrypting the encrypted packet into an intermediate payload by the gateway using a public key, where the public key corresponds to a certificate provisioned to each of the plurality of devices; and decrypting the intermediate payload into a decrypted packet by the gateway using the token.

Abstract: A mobile device that includes an ownership token application program receives user input indicative of a first authentication factor associated with an ownership token bound to an Internet of Things (IoT) device. Responsive to detecting the IoT device in close proximity, the mobile device may obtain a second authentication factor and an IoT device identifier from the IoT device. The mobile device may then provide the obtained factors as authenticating credentials to a token server via a trust application program interface (API). After the server authenticates the mobile device, the server may send the token to the mobile device thereby transferring ownership rights, including access rights, to recipient. The application program and/or the trust API may be configured for one-time access wherein, after the token has been transferred to the mobile device. The discrete electronic device may comprise an Internet of Things (IoT device) that supports wireless, near field communication.

Abstract: Aspects of the present invention provide the ability to enforce access methods on data based upon a policy or policies identified within the metadata of a file. The data is self-protected by including or being wrapped with one or more policy/rule identifiers that act as a form of body armor to the data when in transit or in different situations. In embodiments, access is only granted upon successful authentication and compliance with the identified policy or policies. In embodiments, depending upon the conditions and policies, varying level access may be granted. In embodiments, depending upon the conditions and policies, the system may take one or more mitigations or remedial access levels, such as containerizing, sandboxing, granting limited access, or erasing the data.

Abstract: Systems and methods for distributed authorization are described. In some embodiments, an Information Handling System (IHS) may include a processor; and a memory coupled to the processor, the memory having program instructions stored thereon that, upon execution, cause the IHS to: receive a first authentication material from a first device; identify, based upon a policy stored in the IHS, a second device; and distribute a second authentication material to the second device.

Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine-?-lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from CSE inhibition.

Abstract: GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Abstract: Systems and methods for securing network devices through the use of an out-of-band beacon are described. In some embodiments, a method may include broadcasting, by a gateway, a wireless beacon that is out-of-band with respect to communications between the gateway and a plurality of devices over a network, where the wireless beacon includes a token; receiving an encrypted packet at the gateway as part of the communications; decrypting the encrypted packet into an intermediate payload by the gateway using a public key, where the public key corresponds to a certificate provisioned to each of the plurality of devices; and decrypting the intermediate payload into a decrypted packet by the gateway using the token.

Abstract: Systems and methods for distributed authorization are described. In some embodiments, an Information Handling System (IHS) may include a processor; and a memory coupled to the processor, the memory having program instructions stored thereon that, upon execution, cause the IHS to: receive a first authentication material from a first device; identify, based upon a policy stored in the IHS, a second device; and distribute a second authentication material to the second device.

Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine-?-lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from CSE inhibition.

Abstract: Aspects of the present invention provide the ability to enforce access methods on data based upon a policy or policies identified within the metadata of a file. The data is self-protected by including or being wrapped with one or more policy/rule identifiers that act as a form of body armor to the data when in transit or in different situations. In embodiments, access is only granted upon successful authentication and compliance with the identified policy or policies. In embodiments, depending upon the conditions and policies, varying level access may be granted. In embodiments, depending upon the conditions and policies, the system may take one or more mitigations or remedial access levels, such as containerizing, sandboxing, granting limited access, or erasing the data.

Abstract: Aspects of the present invention provide the ability to enforce access methods on data based upon a policy or policies identified within the metadata of a file. The data is self-protected by including or being wrapped with one or more policy/rule identifiers that act as a form of body armor to the data when in transit or in different situations. In embodiments, access is only granted upon successful authentication and compliance with the identified policy or policies. In embodiments, depending upon the conditions and policies, varying level access may be granted. In embodiments, depending upon the conditions and policies, the system may take one or more mitigations or remedial access levels, such as containerizing, sandboxing, granting limited access, or erasing the data.

Abstract: Aspects of the present invention provide the ability to enforce access methods on data based upon a policy or policies identified within the metadata of a file. The data is self-protected by including or being wrapped with policies/rules that act as a form of body armor to the data when in transit or in different situations. In embodiments, access is only granted upon successful authentication and compliance with the identified policy or policies. In embodiments, depending upon the conditions and policies, varying level access may be granted. In embodiments, depending upon the conditions and policies, the system may take one or more mitigations or remedial access levels, such as containerizing, sandboxing, granting limited access, or erasing the data.

Abstract: Provided are carbazole and carbazole-like compounds (e.g., pyridoindole and pyrrolodipyridine compounds. The compounds can be used to selectively kill cancer cells. Prostate cancer (PCa) is the most frequent neoplastic disease and the second leading cause of cancer-related deaths in men, claiming more than 30,000 men each year in the United States alone. PCa tumors are composed primarily of prostate luminal epithelial cells. Differentiation of prostate luminal epithelial cells is controlled in part by Androgen receptor (AR) driven expression of prostate-specific markers.